Antioxidant effect of short-term hormonal treatment in postmenopausal women. 1999

C Clemente, and M G Caruso, and P Berloco, and M Notarnicola, and B D'Attoma, and A R Osella, and V Guerra, and A Buonsante, and B Giannandrea, and A Di Leo
Laboratory of Biochemistry, Scientific Institute for Digestive Diseases, IRCCS S. De Bellis, Castellana Grotte, Italy.

OBJECTIVE Recent studies have shown that estrogens alone or in association with progestins can exert an antioxidant effect on Low-Density Lipoprotein (LDL) and lipids of platelet membranes. It has been demonstrated that the oxidative modification of LDLs also involving the formation of lipid peroxides, exerts several biological effects that may contribute to the onset and progression of cardiovascular diseases. Therefore, the aim of our study was to evaluate the effect of short-term treatment with oral estrogens alone and estrogens plus progestin on endogenous and copper-induced serum levels of lipid peroxides in postmenopausal women. METHODS Thirty-nine postmenopausal women were randomly divided into three groups: group I was treated with oral conjugated equine estrogens (CEE) for 21 days; group II received oral CEE for 21 days and, after 14 days of this treatment, 5 mg/day of medrogestone was added for 7 days; group III did not receive any therapy (controls). Endogenous and copper-induced serum levels of lipid peroxides were determined before and after 21 days of treatment in the two treated groups and in the control group. RESULTS The serum endogenous levels of lipid peroxides in postmenopausal women did not change after short-term treatment with hormone replacement therapy. Moreover, copper-induced serum levels of lipid peroxides significantly decreased after therapy in both groups I and II. CONCLUSIONS Our data show that hormone replacement therapy (HRT) inhibits lipid peroxidation and may play a role in preventing cardiovascular diseases.

UI MeSH Term Description Entries
D008524 Medrogestone 6,17-Dimethylpregna-4,6-diene-3,20-dione. A synthetic progestational hormone with actions similar to those of progesterone. It is used in the treatment of menstrual irregularities and has also been employed in the treatment of prostatic hypertrophy and endometrial carcinoma. Colpro,Colprone,Prothil
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D004966 Estrogens, Conjugated (USP) A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate. Conjugated Equine Estrogen,Conjugated Estrogen,Estrogenic Substances, Conjugated,Progen,Carentil,Climarest,Climopax,Congest,Conjugated Equine Estrogens,Conjugated Estrogens,Dagynil,Estro-Feminal,Estrogenic Hormones, Conjugated,Estrogens, Conjugated,Femavit,Oestro-Feminal,Oestrofeminal,Prelestrin,Premarin,Presomen,Progens,Transannon,Conjugated Estrogenic Hormones,Conjugated Estrogenic Substances,Equine Estrogen, Conjugated,Equine Estrogens, Conjugated,Estro Feminal,Estrogen, Conjugated,Estrogen, Conjugated Equine,Oestro Feminal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015227 Lipid Peroxidation Peroxidase catalyzed oxidation of lipids using hydrogen peroxide as an electron acceptor. Lipid Peroxidations,Peroxidation, Lipid,Peroxidations, Lipid
D015914 Estrogen Replacement Therapy The use of hormonal agents with estrogen-like activity in postmenopausal or other estrogen-deficient women to alleviate effects of hormone deficiency, such as vasomotor symptoms, DYSPAREUNIA, and progressive development of OSTEOPOROSIS. This may also include the use of progestational agents in combination therapy. Hormone Replacement Therapy, Post-Menopausal,Postmenopausal Hormone Replacement Therapy,Replacement Therapy, Estrogen,Estrogen Progestin Combination Therapy,Estrogen Progestin Replacement Therapy,Estrogen Replacement,Replacement, Estrogen,Therapy, Estrogen Replacement,Estrogen Replacement Therapies,Estrogen Replacements,Hormone Replacement Therapy, Post Menopausal,Replacement Therapies, Estrogen,Replacements, Estrogen,Therapies, Estrogen Replacement
D017698 Postmenopause The physiological period following the MENOPAUSE, the permanent cessation of the menstrual life. Post-Menopause,Post-menopausal Period,Postmenopausal Period,Period, Post-menopausal,Period, Postmenopausal,Post Menopause,Post menopausal Period,Post-Menopauses
D019327 Copper Sulfate A sulfate salt of copper. It is a potent emetic and is used as an antidote for poisoning by phosphorus. It also can be used to prevent the growth of algae. Cupric Sulfate,Blue Vitriol,Sulfate, Copper,Sulfate, Cupric,Vitriol, Blue

Related Publications

C Clemente, and M G Caruso, and P Berloco, and M Notarnicola, and B D'Attoma, and A R Osella, and V Guerra, and A Buonsante, and B Giannandrea, and A Di Leo
June 1979, Maturitas,
C Clemente, and M G Caruso, and P Berloco, and M Notarnicola, and B D'Attoma, and A R Osella, and V Guerra, and A Buonsante, and B Giannandrea, and A Di Leo
June 1985, The Journal of clinical endocrinology and metabolism,
C Clemente, and M G Caruso, and P Berloco, and M Notarnicola, and B D'Attoma, and A R Osella, and V Guerra, and A Buonsante, and B Giannandrea, and A Di Leo
January 1998, Maturitas,
C Clemente, and M G Caruso, and P Berloco, and M Notarnicola, and B D'Attoma, and A R Osella, and V Guerra, and A Buonsante, and B Giannandrea, and A Di Leo
April 1994, The New England journal of medicine,
C Clemente, and M G Caruso, and P Berloco, and M Notarnicola, and B D'Attoma, and A R Osella, and V Guerra, and A Buonsante, and B Giannandrea, and A Di Leo
August 1994, The New England journal of medicine,
C Clemente, and M G Caruso, and P Berloco, and M Notarnicola, and B D'Attoma, and A R Osella, and V Guerra, and A Buonsante, and B Giannandrea, and A Di Leo
July 1994, Thorax,
C Clemente, and M G Caruso, and P Berloco, and M Notarnicola, and B D'Attoma, and A R Osella, and V Guerra, and A Buonsante, and B Giannandrea, and A Di Leo
April 2010, Fertility and sterility,
C Clemente, and M G Caruso, and P Berloco, and M Notarnicola, and B D'Attoma, and A R Osella, and V Guerra, and A Buonsante, and B Giannandrea, and A Di Leo
January 1978, Upsala journal of medical sciences,
C Clemente, and M G Caruso, and P Berloco, and M Notarnicola, and B D'Attoma, and A R Osella, and V Guerra, and A Buonsante, and B Giannandrea, and A Di Leo
July 1997, Maturitas,
C Clemente, and M G Caruso, and P Berloco, and M Notarnicola, and B D'Attoma, and A R Osella, and V Guerra, and A Buonsante, and B Giannandrea, and A Di Leo
November 2005, Fertility and sterility,
Copied contents to your clipboard!